<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:32:49Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8905392" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8905392</identifier>
        <datestamp>2022-03-23</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8905392</article-id>
              <article-id pub-id-type="pmcid">PMC8905392</article-id>
              <article-id pub-id-type="pmc-uid">8905392</article-id>
              <article-id pub-id-type="pmid">35258579</article-id>
              <article-id pub-id-type="pmid">35258579</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2022.0632</article-id>
              <article-id pub-id-type="publisher-id">zoi220042</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Rheumatology</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effect of Pulsed Low-Intensity Ultrasonography on Symptom Relief and Tibiofemoral Articular Cartilage Thickness Among Veterans Affairs Enrollees With Knee Osteoarthritis</article-title>
                <subtitle>A Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Effect of Pulsed Low-Intensity Ultrasonography on Symptoms and Cartilage Thickness in Osteoarthritis</alt-title>
                <alt-title alt-title-type="running-head">Effect of Pulsed Low-Intensity Ultrasonography on Symptoms and Cartilage Thickness in Osteoarthritis</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Sawitzke</surname>
                    <given-names>Allen D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi220042aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jackson</surname>
                    <given-names>Christopher G.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi220042aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi220042aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Carlson</surname>
                    <given-names>Kimberly</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="zoi220042aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bizien</surname>
                    <given-names>Marcel D.</given-names>
                  </name>
                  <degrees>PharmD</degrees>
                  <xref rid="zoi220042aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="zoi220042aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Leiner</surname>
                    <given-names>Mathew</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="zoi220042aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Reda</surname>
                    <given-names>Domenic J.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi220042aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sindowski</surname>
                    <given-names>Tom</given-names>
                  </name>
                  <degrees>BS</degrees>
                  <xref rid="zoi220042aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hanrahan</surname>
                    <given-names>Christopher</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi220042aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi220042aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Spencer</surname>
                    <given-names>Richard G.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi220042aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kwoh</surname>
                    <given-names>C. Kent</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi220042aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>Susan J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi220042aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hose</surname>
                    <given-names>Kalli</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi220042aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Robin</surname>
                    <given-names>Lisa</given-names>
                  </name>
                  <degrees>MA</degrees>
                  <xref rid="zoi220042aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cain</surname>
                    <given-names>Donna W.</given-names>
                  </name>
                  <degrees>BA</degrees>
                  <xref rid="zoi220042aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Taylor</surname>
                    <given-names>Meredith D.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi220042aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bangerter</surname>
                    <given-names>Neal</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi220042aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                  <xref rid="zoi220042aff12" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                  <xref rid="zoi220042aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Finco</surname>
                    <given-names>Martha</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="zoi220042aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Clegg</surname>
                    <given-names>Daniel O.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi220042aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi220042aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zoi220042aff1"><label>1</label>Department of Medicine, University of Utah, Salt Lake City</aff>
              <aff id="zoi220042aff2"><label>2</label>George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah</aff>
              <aff id="zoi220042aff3"><label>3</label>Edward Hines Junior VA Hospital Cooperative Studies Program Coordinating Center, Hines, Illinois</aff>
              <aff id="zoi220042aff4"><label>4</label>VA Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico</aff>
              <aff id="zoi220042aff5"><label>5</label>School of Pharmacy, University of New Mexico, Albuquerque, New Mexico</aff>
              <aff id="zoi220042aff6"><label>6</label>National Institutes of Health/National Institute on Aging, Laboratory of Clinical Investigation, Baltimore, Maryland</aff>
              <aff id="zoi220042aff7"><label>7</label>University of Arizona Arthritis Center, University of Arizona, Tucson</aff>
              <aff id="zoi220042aff8"><label>8</label>VA San Diego Healthcare System, San Diego, California</aff>
              <aff id="zoi220042aff9"><label>9</label>Department of Medicine, San Diego VA Medical Center, San Diego, California</aff>
              <aff id="zoi220042aff10"><label>10</label>Department of Electrical &amp; Computer Engineering, Brigham Young University, Provo, Utah</aff>
              <aff id="zoi220042aff11"><label>11</label>Department of Radiology, University of Utah, Salt Lake City</aff>
              <aff id="zoi220042aff12"><label>12</label>Department of Orthopedics, University of Utah, Salt Lake City</aff>
              <aff id="zoi220042aff13"><label>13</label>Department of Bioengineering, Imperial College London, London, United Kingdom</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> January 7, 2022.</p>
                <p content-type="published-online"><bold>Published:</bold> March 8, 2022. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2022.0632</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2022 Sawitzke AD et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi220042cor1"><bold>Corresponding Author:</bold> Allen D. Sawitzke, MD, University of Utah Rheumatology Division, 30N Medical Dr, 4B200, Salt Lake City, UT 84132 (<email xlink:href="allen.sawitzke@hsc.utah.edu">allen.sawitzke@hsc.utah.edu</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Sawitzke and Clegg had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design: </italic>Sawitzke, Jackson, Carlson, Bizien, Reda, Hanrahan, Spencer, Kwoh, Lee, Robin, Bangerter, Finco, Clegg.</p>
                <p><italic>Acquisition, analysis, or interpretation of data: </italic>Sawitzke, Jackson, Carlson, Bizien, Leiner, Reda, Sindowski, Hanrahan, Spencer, Lee, Hose, Cain, Taylor, Bangerter, Finco, Clegg.</p>
                <p><italic>Drafting of the manuscript: </italic>Sawitzke, Jackson, Carlson, Bizien, Leiner, Sindowski, Spencer, Lee, Bangerter, Finco, Clegg.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content: </italic>Sawitzke, Jackson, Carlson, Bizien, Reda, Hanrahan, Spencer, Kwoh, Hose, Robin, Cain, Taylor, Bangerter, Finco, Clegg.</p>
                <p><italic>Statistical analysis: </italic>Sawitzke, Jackson, Carlson, Leiner, Spencer.</p>
                <p><italic>Obtained funding: </italic>Jackson, Reda, Spencer, Lee, Bangerter, Clegg.</p>
                <p><italic>Administrative, technical, or material support: </italic>Sawitzke, Jackson, Carlson, Bizien, Reda, Sindowski, Hanrahan, Spencer, Lee, Robin, Cain, Taylor, Bangerter, Finco, Clegg.</p>
                <p><italic>Supervision: </italic>Jackson, Bizien, Reda, Lee, Taylor, Bangerter, Clegg.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Kwoh reported receiving grants from AbbVie, EMD Serono, Lilly, Pfizer, GSK, and Cumberland Pharmaceuticals; personal fees from EMD Serono, Thusane, Express Scripts, Regeneron, Taiwan Liposome Company, Amzell, NZ, LG Chem, Novartis, Focus Communications, PRIME Education, LLC, Kolon Tissue Gene, and served as an unpaid member of International Chinese Osteoarthritis Research Society board outside the submitted work. Dr Taylor reported receiving grants from US Department of Veterans Affairs during the conduct of the study. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This study was funded by the US Department of Veterans Affairs Clinical Sciences Research &amp; Development Program, Cooperative Clinical Trial Award Program (award CX13-007). This work was supported in part by the National Institutes of Health, National Institute on Aging, Intramural Research Program (Dr Spencer).</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p><bold>Disclaimer:</bold> The opinions herein are those of the individual authors and the contents do not represent views of the Department of Veterans Affairs or the US Government.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI220042-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
                <p content-type="funding-statement"><bold>Additional Contributions:</bold> Bioventus donated the ultrasonographic devices, and Tamara Haegerich, PhD (Edward Hines Junior VA Hospital), provided guidance and review; no financial compensation was provided.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2022-03-08T10:00">
                <day>8</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>8</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>5</volume>
              <issue>3</issue>
              <elocation-id>e220632</elocation-id>
              <history>
                <date date-type="received">
                  <day>30</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>7</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2022 Sawitzke AD et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e220632.pdf">jamanetwopen-e220632.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.0632"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi220042-1">
                  <title>Question</title>
                  <p>Does 48 weeks of pulsed low-intensity ultrasonography (PLIUS) provide therapeutic benefit for patients with idiopathic knee osteoarthritis?</p>
                </sec>
                <sec id="ab-zoi220042-2">
                  <title>Findings</title>
                  <p>In this randomized clinical trial of 132 adults with symptomatic and radiographic idiopathic knee osteoarthritis, no statistically significant difference was found between PLIUS and sham therapies for clinical symptoms or tibiofemoral cartilage thickness, the coprimary outcomes.</p>
                </sec>
                <sec id="ab-zoi220042-3">
                  <title>Meaning</title>
                  <p>PLIUS as applied in this trial was not effective in ameliorating symptoms or slowing cartilage loss associated with idiopathic knee osteoarthritis.</p>
                </sec>
              </abstract>
              <abstract>
                <sec id="ab-zoi220042-4">
                  <title>Importance</title>
                  <p>Osteoarthritis (OA) is a major cause of disability in the US, with no approved treatments to slow progression, but animal models suggest that pulsed low-intensity ultrasonography (PLIUS) may promote cartilage growth.</p>
                </sec>
                <sec id="ab-zoi220042-5">
                  <title>Objective</title>
                  <p>To evaluate the efficacy of PLIUS in providing symptom reduction and decreased loss of tibiofemoral cartilage thickness in patients with knee OA.</p>
                </sec>
                <sec id="ab-zoi220042-6">
                  <title>Design, Setting, and Participants</title>
                  <p>A phase 2A, sham-controlled, parallel, double-blind randomized clinical trial was conducted at 2 Veterans Affairs hospitals in Salt Lake City, Utah, and San Diego, California, from May 22, 2015, to January 31, 2019. Data were analyzed from June 27, 2020, to October 20, 2020. Participants recruited through the US Department of Veterans Affairs (N = 132) with clinical and radiographic evidence of early knee OA were randomly assigned to receive PLIUS or a sham device, self-administered for 20 minutes daily over the medial compartment of the knee. All enrollees participated in a 4-week prerandomization sham run-in period, followed by a 48-week treatment period. Randomization was stratified by study site and Kellgren-Lawrence grades 1 (n = 15), 2 (n = 51), and 3 (n = 66).</p>
                </sec>
                <sec id="ab-zoi220042-7">
                  <title>Intervention</title>
                  <p>Participants either received 48 weeks of PLIUS or sham ultrasonography.</p>
                </sec>
                <sec id="ab-zoi220042-8">
                  <title>Main Outcomes and Measures</title>
                  <p>The trial incorporated 2 coprimary outcomes: symptomatic improvement assessed by Outcome Measures in Rheumatology Clinical Trials–Osteoarthritis Research Society International Responder Criteria (ie, met if either &gt;50% improvement in pain and function with at least a 20% absolute improvement of at least 2 of the following 3 factors: improvement by at least 20% [pain, function, and patient global assessment] with at least a 10-mm absolute improvement), and cartilage preservation assessed as change in central medial femoral condyle cartilage thickness by magnetic resonance imaging. Intention-to-treat analysis was used.</p>
                </sec>
                <sec id="ab-zoi220042-9">
                  <title>Results</title>
                  <p>The mean (SD) participant age was 63.6 (10.7) years and 119 were men (90.2%). The mean (SD) duration of OA symptoms was 13.4 (12.3) years. In the PLIUS group, 70.4% (95% CI, 58.2%-82.6%) of the participants experienced symptomatic improvement, compared with 67.3% (95% CI, 54.9%-79.7%) of participants in the sham group (<italic>P</italic> = .84); there was no statistically significant difference in response rates between the treatment groups, and the between-group rate difference of 3.1% (95% CI, –14.3% to 20.5%) did not meet the predefined 10% threshold for clinically significant symptomatic improvement from application of PLIUS. At 48 weeks of treatment, central medial femoral condyle cartilage thickness decreased by a mean (SD) of 73.8 (168.1) μm in the PLIUS group and by 42.2 (297.0) μm in the sham group. This 48-week mean change between the 2 groups did not reach statistical significance (<italic>P</italic> = .44), and the between-group 48-week difference of –31.7 μm (95% CI, –129.0 μm to 65.7 μm) did not meet the predefined threshold. There were 99 nonserious adverse events in the PLIUS group and 89 in the sham group during the trial. No serious adverse events were deemed related to the study device.</p>
                </sec>
                <sec id="ab-zoi220042-10">
                  <title>Conclusions and Relevance</title>
                  <p>PLIUS, as implemented in this study, demonstrated neither symptomatic benefit nor a decrease in loss of tibiofemoral cartilage thickness in knee OA.</p>
                </sec>
                <sec id="ab-zoi220042-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02034409" ext-link-type="uri">NCT02034409</ext-link></p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This randomized clinical trial evaluates the use of pulsed low-intensity ultrasonography for symptom relief and cartilage loss in individuals with osteoarthritis of the knee.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI220042">
              <title>Introduction</title>
              <p>Osteoarthritis (OA) affects almost 27 million individuals in the US with an estimated net cost of more than $80 billion per year.<sup><xref rid="zoi220042r1" ref-type="bibr">1</xref>,<xref rid="zoi220042r2" ref-type="bibr">2</xref></sup> Knee OA is particularly common with advancing age, with 30% of individuals older than 45 years having radiographic changes and approximately half of those being symptomatic.<sup><xref rid="zoi220042r3" ref-type="bibr">3</xref></sup> It is the leading cause of lower extremity disability in the US and is the most frequent indication for total knee replacement.<sup><xref rid="zoi220042r4" ref-type="bibr">4</xref></sup> By 2030, an estimated 60 million people in the US will be affected.<sup><xref rid="zoi220042r5" ref-type="bibr">5</xref></sup> Medical management at present is directed only at symptom relief<sup><xref rid="zoi220042r6" ref-type="bibr">6</xref></sup> and, at best, has marginal long-term efficacy. Osteoarthritis is known to occur disproportionately in members of the armed services,<sup><xref rid="zoi220042r7" ref-type="bibr">7</xref></sup> with the burden of disease evidenced by the fact that within the Veterans Affairs system, total knee replacement is a very common elective surgical procedure.</p>
              <p>Despite substantial progress in understanding the pathogenesis of OA, no disease-modifying interventions to slow or stop its progression have been given regulatory approval.<sup><xref rid="zoi220042r3" ref-type="bibr">3</xref>,<xref rid="zoi220042r8" ref-type="bibr">8</xref></sup> Several surgical techniques intended to repair, regenerate, or replace damaged cartilage have been attempted, including microfracture,<sup><xref rid="zoi220042r9" ref-type="bibr">9</xref></sup> autograft and allograft transplants,<sup><xref rid="zoi220042r10" ref-type="bibr">10</xref></sup> and autologous chondrocyte implantation<sup><xref rid="zoi220042r11" ref-type="bibr">11</xref></sup>; however, long-term outcomes have been disappointing for all of these procedures.</p>
              <p>Pulsed low-intensity ultrasonography (PLIUS) has long been used for fracture healing<sup><xref rid="zoi220042r12" ref-type="bibr">12</xref>,<xref rid="zoi220042r13" ref-type="bibr">13</xref></sup> and is also known to increase cartilage matrix production.<sup><xref rid="zoi220042r14" ref-type="bibr">14</xref>,<xref rid="zoi220042r15" ref-type="bibr">15</xref></sup> Both in vitro and animal studies suggest the potential for PLIUS in promoting cartilage growth<sup><xref rid="zoi220042r16" ref-type="bibr">16</xref>,<xref rid="zoi220042r17" ref-type="bibr">17</xref>,<xref rid="zoi220042r18" ref-type="bibr">18</xref>,<xref rid="zoi220042r19" ref-type="bibr">19</xref>,<xref rid="zoi220042r20" ref-type="bibr">20</xref></sup> through molecular-level signaling,<sup><xref rid="zoi220042r21" ref-type="bibr">21</xref></sup> increased aggrecan and collagen gene expression,<sup><xref rid="zoi220042r18" ref-type="bibr">18</xref></sup> related protein production in cell culture systems,<sup><xref rid="zoi220042r17" ref-type="bibr">17</xref></sup> and improved cartilage tissue integrity in animal OA models.<sup><xref rid="zoi220042r16" ref-type="bibr">16</xref>,<xref rid="zoi220042r20" ref-type="bibr">20</xref>,<xref rid="zoi220042r22" ref-type="bibr">22</xref></sup> PLIUS has also been found to attenuate cartilage degradation in the guinea pig model of idiopathic age-associated OA.<sup><xref rid="zoi220042r23" ref-type="bibr">23</xref></sup></p>
              <p>In preliminary human studies, PLIUS has resulted in reduced OA symptoms,<sup><xref rid="zoi220042r24" ref-type="bibr">24</xref>,<xref rid="zoi220042r25" ref-type="bibr">25</xref>,<xref rid="zoi220042r26" ref-type="bibr">26</xref></sup> and a disease-modifying potential for PLIUS has been suggested by a post hoc subgroup analysis of an additional human study.<sup><xref rid="zoi220042r27" ref-type="bibr">27</xref></sup> There have been indicators of a positive effect on cartilage repair.<sup><xref rid="zoi220042r28" ref-type="bibr">28</xref>,<xref rid="zoi220042r29" ref-type="bibr">29</xref></sup> The present sham-controlled, parallel, double-blind, phase 2A randomized clinical trial was undertaken as a pilot to extend these preliminary findings and determine whether a subsequent phase 2b or phase 3 trial of PLIUS for OA therapy would be warranted.</p>
            </sec>
            <sec id="H1-2-ZOI220042">
              <title>Methods</title>
              <sec id="H2-1-ZOI220042">
                <title>Participants</title>
                <p>Study participants were beneficiaries of the Department of Veterans Affairs with a previous service history, recruited from Salt Lake City, Utah, or San Diego, California, VA research centers from May 22, 2015, until January 31, 2019. Data were analyzed from June 27, 2020, to October 20, 2020. Demographic data collected included age, sex, race, and ethnicity. Data on race were obtained as required by the funding agency but were not included in the analysis owing to the small numbers. Inclusion criteria comprised age of at least 40 years, clinical symptoms of OA defined by knee pain for at least 6 months and on most days during the month preceding study entry, and radiographic evidence of OA defined by Kellgren-Lawrence grade (KLG) (1: doubtful narrowing of joint space, possible osteophytic lipping; 2: definite osteophytes and possible narrowing of joint space; and 3: moderate multiple osteophytes, definite narrowing of joint space, some sclerosis, and possible deformity) evaluated from posterior-anterior weightbearing knee radiographs (SynaFlexer positioning device; Synarc Inc).<sup><xref rid="zoi220042r30" ref-type="bibr">30</xref></sup> Study inclusion was initially restricted to individuals with KLG 2 and 3 to ensure established OA and minimize ceiling effects. However, to enhance recruitment, a subsequent protocol amendment allowed inclusion of participants with KLG 1, who were then added to the KLG 2 cohort. Eligible individuals were required to have a summed pain score of 125 to 400 (greatest level of pain) on their more symptomatic (index) knee according to the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), using a 0- to 500-point score visual analog scale, with the highest value indicating the most pain, stiffness, and limitation of function,<sup><xref rid="zoi220042r31" ref-type="bibr">31</xref>,<xref rid="zoi220042r32" ref-type="bibr">32</xref></sup> and to be categorized within American Rheumatism Association functional class I (completely able to perform usual activities of daily living), II (able to do usual self-care and vocational activities but limited in avocational activities), or III (able to perform usual self-care activities but limited in vocational and avocational activities).<sup><xref rid="zoi220042r33" ref-type="bibr">33</xref></sup></p>
                <p>Exclusion criteria included a concurrent medical or rheumatologic condition that could confound evaluation of the index joint, predominant patellofemoral disease (as determined by the investigator), a history of substantial trauma or surgery to the index knee, or a coexisting morbidity that jeopardized successful completion of the trial. The institutional review boards of both participating VA medical centers approved the study, and all patients gave written informed consent; financial compensation was provided. The trial protocol is available in <xref rid="note-ZOI220042-1-s" ref-type="supplementary-material">Supplement 1</xref>. This study followed the Consolidated Standards of Reporting Trials (<ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) reporting guideline for randomized clinical trials.<sup><xref rid="zoi220042r34" ref-type="bibr">34</xref>,<xref rid="zoi220042r35" ref-type="bibr">35</xref></sup></p>
              </sec>
              <sec id="H2-2-ZOI220042">
                <title>Treatment Regimens</title>
                <p>The study consisted of 3 distinct phases: period 1, initial screening; period 2, a 4-week prerandomization sham run-in period for the participants to develop facility in using the device; and period 3, a 48-week sham-controlled treatment period. Permuted-block randomization was used with random block sizes, stratified by clinical centers and baseline KLG. The randomization code list was developed by the Department of Veterans Affairs Cooperative Studies Program Coordinating Center in Hines, Illinois, using SAS, version 9.4 (SAS Institute Inc). Eligible patients were randomized (1:1) to daily self-administered 20-minute treatment with PLIUS or sham control. Based on the randomization, both sham and active devices were coded and distributed to participating research sites by the Department of Veterans Affairs Cooperative Studies Program Pharmacy Center.</p>
                <p>Participants were allowed the use of acetaminophen (up to 3000 mg/d) and/or immediate-release tramadol (up to 200 mg/d) as rescue analgesia for severe knee pain throughout the trial, except for the 24 hours before each clinical evaluation. A stable daily dose of nonsteroidal anti-inflammatory drugs for pain unrelated to OA was also permitted. Patients were evaluated at baseline and 2, 4, 8, 12, 24, 36, and 48 weeks after randomization.</p>
              </sec>
              <sec id="H2-3-ZOI220042">
                <title>Outcome Measures</title>
                <p>The study was designed with symptom improvement and preservation of cartilage as coprimary outcome measures because each is considered an equally important target in the treatment of OA. Symptom reduction was examined using the Outcome Measures in Rheumatology Clinical Trials–Osteoarthritis Research Society International (OMERACT-OARSI) response rate.<sup><xref rid="zoi220042r36" ref-type="bibr">36</xref></sup> For this outcome, a clinical response is achieved if there is either greater than 50% improvement in pain and function with at least a 20% absolute improvement or at least 2 of 3 factors (pain, function, and patient global assessment) improve by at least 20%, with at least a 10-mm absolute improvement.</p>
                <p>Disease progression in OA is typically accompanied by cartilage loss. Hence, the structural outcome measure used in this study was change in the thickness of the articular cartilage within the tibiofemoral joint from baseline to 48 weeks determined by magnetic resonance imaging (MRI) assessment of the central medial femoral condyle cartilage thickness.<sup><xref rid="zoi220042r37" ref-type="bibr">37</xref>,<xref rid="zoi220042r38" ref-type="bibr">38</xref>,<xref rid="zoi220042r39" ref-type="bibr">39</xref>,<xref rid="zoi220042r40" ref-type="bibr">40</xref>,<xref rid="zoi220042r41" ref-type="bibr">41</xref></sup> The MRI protocol developed for the Osteoarthritis Initiative on 3T MRI scanners (Siemens Healthineers) was adopted, because a large body of work exists validating this protocol for measurements of cartilage morphometry. Cartilage volumes were segmented manually after a first-pass automated segmentation using Colipe software version 14.10.1 revision 264 (Qmetrics Technologies). All final manual segmentations were performed by the same reader (M.D.T.), with blinding to time point in the study, with subcompartmental analyses of cartilage volume and thickness performed from which central medial femoral condyle cartilage thickness was derived. A difference of at least 33 μm between the PLIUS and sham group at 1 year was selected as a signal of positive response.</p>
                <p>Secondary outcome measures, selected a priori in accordance with the preliminary recommendations of the OARSI task force,<sup><xref rid="zoi220042r42" ref-type="bibr">42</xref></sup> included pain, stiffness, and function WOMAC subscales along with the total score<sup><xref rid="zoi220042r32" ref-type="bibr">32</xref></sup>; the patient’s global assessment of disease status<sup><xref rid="zoi220042r43" ref-type="bibr">43</xref></sup>; response to therapy evaluated through the use of a 100-mm visual analog scale on which higher scores indicate more severe disease; the investigator’s global assessment of disease status and response to therapy, also assessed with a 100-mm visual analog scale; and constant, intermittent, and total pain subscales according to the Intermittent and Constant Osteoarthritis Pain scoring system, with higher values indicating more severe pain.<sup><xref rid="zoi220042r43" ref-type="bibr">43</xref></sup> Six serum and urine biomarkers of cartilage breakdown were also measured: serum C-terminal telopeptide of collagen II, urine C-terminal telopeptide of collagen II, serum cartilage oligomeric matrix proteins, serum collagen II cleavage, serum nitrated collagen II cleavage, and urine nitrated collagen II cleavage. Samples were collected at baseline and 24 and 48 weeks after initiation of the treatment period. Morning second-void urine samples were collected and frozen for urine biomarker measurements, with values adjusted using serum creatinine level.<sup><xref rid="zoi220042r44" ref-type="bibr">44</xref></sup> All biomarkers testing was conducted by Artialis Group.</p>
              </sec>
              <sec id="H2-4-ZOI220042">
                <title>Adverse Events</title>
                <p>Adverse events were assessed and graded for severity and attributability by the investigator (C.G.J. and K.H.) at the study visit. Adverse events included adverse device events, non–device-related adverse events, and serious adverse events. Adverse device events were further categorized into adverse reactions, suspected adverse reactions, and unanticipated adverse device events. An independent data and safety monitoring committee performed periodic reviews of adverse events.</p>
              </sec>
              <sec id="H2-5-ZOI220042">
                <title>Device</title>
                <p>PLIUS was self-administered using a lightweight, portable US Food and Drug Administration–approved device (Sonic Accelerated Fracture Healing System; Bioventus LLC), currently in clinical use for fracture healing.<sup><xref rid="zoi220042r45" ref-type="bibr">45</xref></sup> An investigational device exemption was obtained to use the device in this trial. The device produced a spatial average–temporal average power of 30 mW/cm<sup>2</sup>, with a sinusoidal waveform of frequency 1.5 MHz. The pulse burst frequency was 1 kHz and the duration was 200 ms. Adherence was ascertained through interrogation of the PLIUS device on repeat visits, with the number and duration of treatment sessions recorded internally.</p>
              </sec>
              <sec id="H2-6-ZOI220042">
                <title>Analytic Plan</title>
                <p>The purpose of this phase 2A trial was to determine whether potential superiority existed in either or both primary outcomes, which would justify a larger, more definitive study of PLIUS. For that reason, the sample size was calculated with a signal detection approach (ranking and selection method). No multiplicity adjustment for the 2 coprimary outcomes was conducted.<sup><xref rid="zoi220042r46" ref-type="bibr">46</xref>,<xref rid="zoi220042r47" ref-type="bibr">47</xref>,<xref rid="zoi220042r48" ref-type="bibr">48</xref></sup></p>
                <p>The 48-week outcomes were assessed independently. For the 48-week OMERACT-OARSI response, the minimally clinically significant difference is an absolute rate difference of 10% between 2 groups. A total sample size of 144 provides a probability of at least 0.885 of detecting a treatment effect. For central medial femoral condyle cartilage thickness, a difference in measurement of 33 μm at 48 weeks, with a total sample size of 144, results in a 90% probability of detecting a positive effect.<sup><xref rid="zoi220042r37" ref-type="bibr">37</xref></sup> All other outcomes were secondary and considered exploratory.</p>
              </sec>
              <sec id="H2-7-ZOI220042">
                <title>Statistical Analysis</title>
                <p>Statistical analyses were conducted under intention-to-treat principles. SAS, version 9.4, was used for all analyses, and all comparisons were 2-sided with a significance level of <italic>P</italic> &lt; .05. Comparison of baseline characteristics between PLIUS and sham groups was conducted using the <italic>t</italic> test, χ<sup>2</sup> test, Fisher exact test, or Wilcoxon rank-sum test. Each coprimary outcome (ie, 48-week OMERACT-OARSI response and 48-week central medial femoral condyle cartilage thickness change score) was assessed independently and compared in the PLIUS and sham groups to determine whether the difference between groups exceeded the a priori–specified threshold. All outcome measures were analyzed using a mixed-effects model that included all available follow-up time points without adjustment for missing values. The key analysis for secondary outcomes was the interaction between time and treatment group.</p>
              </sec>
            </sec>
            <sec id="H1-3-ZOI220042">
              <title>Results</title>
              <sec id="H2-8-ZOI220042">
                <title>Participant Characteristics</title>
                <p>As detailed in <xref rid="zoi220042f1" ref-type="fig">Figure 1</xref>, a total of 4879 patients were screened and 276 patients were assessed for eligibility. There were 140 screen exclusions, leaving 136 randomized participants. The most common reasons for screen exclusion were not meeting radiographic criteria (78 patients [56%]) and WOMAC pain scores less than 100 or greater than 400 (26 [19%]). Among patients randomized, 4 were misrandomized and excluded as early terminations, leading to a total study population of 132. In addition, there were 27 terminations before completion of the study: 15 of 67 (22%) participants in the PLIUS group and 12 of 65 (19%) in the sham group.</p>
                <fig position="float" id="zoi220042f1" fig-type="figure">
                  <label>Figure 1. </label>
                  <caption>
                    <title>Participant Flow Diagram</title>
                    <p>Outcome Measures in Rheumatology Clinical Trials–Osteoarthritis Research Society International (OMERACT-OARSI) was used as the symptomatic outcome measure in 54 patients in the pulsed low-intensity ultrasonography (PLIUS) cohort and 55 patients in the sham cohort. Central medial femoral condyle cartilage thickness was used as the structural outcome measure in 51 patients in the PLIUS cohort and 48 patients in the sham cohort. WOMAC indicates Western Ontario and McMaster Universities Osteoarthritis Index.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e220632-g001" position="float"/>
                </fig>
                <p>Baseline characteristics are detailed in <xref rid="zoi220042t1" ref-type="table">Table 1</xref>. The cohort self-identified as mean (SD) age, 63.6 (10.7) years, comprising 119 men (90.2%) and 13 women (9.8%). Self-reported race and ethnicity was as follows: American Indian/Alaskan Native, 8 (6.1%), Asian, 8 (6.1%), Black/African American (12 (9.1%), Native Hawaiian/Pacific Islander, 4 (3.0%), White, 108 (81.8%), and other (Latin, Mexican, Filipina, Spanish, and Puerto Rican), 7 (5.3%). The mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) for 130 randomized participants was 31.7 (5.5). The mean (SD) duration of OA symptoms was 13.4 (12.3) years. There were 15 patients with KLG grade 1, 51 with grade 2, and 66 with grade 3. Other patient characteristics were well balanced between treatment groups. Ultrasonographic device adherence data averaged 90% or higher for both groups.</p>
                <table-wrap position="float" id="zoi220042t1">
                  <label>Table 1. </label>
                  <caption>
                    <title>Baseline Characteristics by Study Group</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="52.25%" span="1"/>
                    <col width="16.41%" span="1"/>
                    <col width="15.3%" span="1"/>
                    <col width="16.04%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                        <th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">No. (%)</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">PLIUS (n = 67)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Sham (n = 65)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Total (N = 132)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">62.9 (10.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">64.4 (10.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">63.6 (10.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (9.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (10.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 (9.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">61 (91.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">58 (89.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">119 (90.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race<xref rid="zoi220042t1n1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> American Indian/Alaskan Native</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (7.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (4.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (6.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asian</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (7.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (4.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (6.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black/African American</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (10.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (7.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 (9.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Native Hawaiian/Pacific Islander</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (4.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (1.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (3.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">53 (79.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">55 (84.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">108 (81.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other (Latin, Mexican, Filipina, Spanish, Puerto Rican)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (7.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (3.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (5.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ethnicity</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cuban</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (1.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mexican, Mexican American, Chicano</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (10.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (6.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 (8.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Not Spanish, Hispanic, Latino</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54 (80.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">55 (84.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">109 (82.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Puerto Rican</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (3.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (3.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (3.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other (Spanish, Hispanic, Latino)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (4.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (6.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (5.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI, No.</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">64</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">130</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31.8 (5.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31.6 (5.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31.7 (5.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Years with OA, mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15.0 (13.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11.7 (11.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13.4 (12.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Years since OA diagnosis, mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10.4 (10.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7.7 (9.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9.1 (10.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">ARA functional class No. (%)<xref rid="zoi220042t1n2" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> I</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (3.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> II</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">52 (77.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">48 (73.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">100 (75.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> III</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 (19.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">17 (26.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30 (22.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> IV</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Kellgren-Lawrence grade<xref rid="zoi220042t1n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (11.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (10.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (11.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">25 (37.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">26 (40.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">51 (38.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">34 (50.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">32 (49.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66 (50.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Global assessment of disease status score, mean (SD)<xref rid="zoi220042t1n4" ref-type="table-fn"><sup>d</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Patient</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">50.4 (22.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">53.0 (17.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">51.7 (20.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Physician</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">58.0 (27.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">63.7 (22.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">60.8 (25.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">WOMAC score, mean (SD)<xref rid="zoi220042t1n5" ref-type="table-fn"><sup>e</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pain subscale</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">228.5 (76.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">250.4 (78.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">239.3 (77.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Stiffness subscale</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">97.9 (41.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">109.0 (46.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">103.4 (44.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Functional subscale</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">755.0 (316.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">855.9 (276.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">804.7 (307.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Total</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1081.4 (407.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1215.3 (378.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1147.3 (397.5)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: ARA, American Rheumatism Association; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); OA, osteoarthritis; PLIUS, pulsed low-intensity ultrasonography; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.</p>
                    <fn id="zoi220042t1n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Race was reported by participant and more than 1 answer was allowed; hence, the percentages sum to more than 100.</p>
                    </fn>
                    <fn id="zoi220042t1n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Class I: completely able to perform usual activities of daily living, II: able to do usual self-care and vocational activities but limited in avocational activities, and III: able to perform usual self-care activities but limited in vocational and avocational activities.</p>
                    </fn>
                    <fn id="zoi220042t1n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Grade 1: doubtful narrowing of joint space, possible osteophytic lipping; 2: definite osteophytes and possible narrowing of joint space; and 3: moderate multiple osteophytes, definite narrowing of joint space, some sclerosis, and possible deformity.</p>
                    </fn>
                    <fn id="zoi220042t1n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Measured on a visual analog scale (0-100) rated by patient or clinician for overall assessment of knee arthritis severity. Larger numbers are more severe conditions.</p>
                    </fn>
                    <fn id="zoi220042t1n5">
                      <label>
                        <sup>e</sup>
                      </label>
                      <p>Higher values indicate more pain, stiffness, and functional limitations.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="H2-9-ZOI220042">
                <title>Outcomes</title>
                <p>The primary analysis of the symptomatic coprimary OMERACT-OARSI outcome showed a response of 70.4% (95% CI, 58.2%-82.6%) in the PLIUS group and 67.3% (95% CI, 54.9%-79.7%) in the sham group as assessed at 48 weeks of treatment (<italic>P</italic> = .84). The between-group difference of 3.1% (95% CI, –14.3% to 20.5%) did not meet the difference threshold of at least 10%. At week 48, the mean (SD) PLIUS group cartilage thickness decreased more than the sham group (73.8 [168.1] vs 42.2 [297.0] μm), with a between-group 48-week average change score of –31.7 μm (95% CI, –129.0 μm to 65.7 μm). This change did not meet the threshold of a cartilage difference of at least 33 μm. Most participants lost cartilage, with no statistically significant difference between the 2 groups (<xref rid="zoi220042f2" ref-type="fig">Figure 2</xref>).</p>
                <fig position="float" id="zoi220042f2" fig-type="figure">
                  <label>Figure 2. </label>
                  <caption>
                    <title>Baseline vs Final Cartilage Thickness</title>
                    <p>Association between central medial femoral condyle cartilage (CCMF) before and after 48 weeks of pulsed low-intensity ultrasonography (PLIUS) or sham treatment. The solid line indicates no change. Data points above the dashed line represent structural responders, ie, loss in cartilage less than 33 μm.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e220632-g002" position="float"/>
                </fig>
                <p>Secondary outcome results are reported in <xref rid="zoi220042t2" ref-type="table">Table 2</xref>. There were 53 serious adverse events and 188 postrandomization nonserious adverse events (99 in the PLIUS group, 89 in the sham group) during the trial. No serious adverse events were deemed related to the study device.</p>
                <table-wrap position="float" id="zoi220042t2">
                  <label>Table 2. </label>
                  <caption>
                    <title>Primary and Secondary Outcomes</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="22.19%" span="1"/>
                    <col width="3.7%" span="1"/>
                    <col width="8.59%" span="1"/>
                    <col width="15.88%" span="1"/>
                    <col width="3.7%" span="1"/>
                    <col width="8.59%" span="1"/>
                    <col width="13.01%" span="1"/>
                    <col width="18.17%" span="1"/>
                    <col width="6.17%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Outcome</th>
                        <th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">PLIUS</th>
                        <th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Sham</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Difference</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value<xref rid="zoi220042t2n1" ref-type="table-fn"><sup>a</sup></xref></th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">No.</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Mean (SD)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Change from baseline (95% CI)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">No.</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Mean (SD)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Change from baseline</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Between PLIUS and sham (95% CI)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="9" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Primary outcomes</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Cartilage thickness, μm</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">61</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1321.1 (291.8)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–73.8 (–122.6 to –25.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">61</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1333.6 (334.1)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–42.2 (–126.6 to 42.2)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–31.7 (–129.0 to 65.7)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.44</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">51</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1257.5 (280.2)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">52</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1298.3 (216.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">OMERACT-OARSI, No. (%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Change</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">38 (70.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">37 (67.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.84<xref rid="zoi220042t2n2" ref-type="table-fn"><sup>b</sup></xref></td>
                      </tr>
                      <tr>
                        <td colspan="9" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Secondary outcomes</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">WOMAC scale<xref rid="zoi220042t2n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Pain</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">228.5 (76.0)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–93.4 (–124.4 to –62.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">250.4 (78.5)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–117.1 (–146.2 to –87.9)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">23.7 (–18.4 to 65.8)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.55</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">126.1 (121.0)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">130.1 (116.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Stiffness</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">97.9 (41.9)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–37.1 (–51.6 to –22.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">109.0 (46.0)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–49.8 (–64.6 to –35.1)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">12.7 (–7.7 to 33.2)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.67</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">57.4 (51.7)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">61.0 (54.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Functional limitation</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">755.0 (316.7)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–283.1 (–399.7 to –166.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">855.9 (290.3)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–407.3 (–510.8 to –303.7)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">124.1 (–29.8 to 278.1)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.17</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">447.6 (415.6)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">450.9 (393.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Total</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1081.4 (407.6)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–413.6 (–571.4 to –255.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1215.3 (378.0)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–574.1 (–713.8 to –434.4)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">160.6 (–47.61 to 368.8)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.24</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">631.1 (581.8)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">642.1 (554.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Global assessment<xref rid="zoi220042t2n4" ref-type="table-fn"><sup>d</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Patient</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">50.4 (22.5)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–17.6 (–26.3 to –9.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">53.0 (17.4)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–23.7 (–30.8 to –16.5)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">6.0 (–5.1 to 17.1)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.84</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30.5 (26.3)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">29.7 (25.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Investigator</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">58.0 (27.5)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–18.9 (–27.9 to –10.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">63.7 (22.3)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–28.6 (–36.6 to –20.6)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">9.7 (–2.1 to 21.5)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.15</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">38.6 (28.0)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">35.1 (29.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">ICOAP subscales<xref rid="zoi220042t2n5" ref-type="table-fn"><sup>e</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Constant pain</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                        <td valign="middle" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">42.5 (19.5)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–13.7 (–20.7 to –6.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">44.7 (16.9)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–18.4 (–24.0 to –12.8)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">4.7 (–4.2 to 13.5)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.92</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">26.0 (24.8)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">26.4 (22.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Intermittent pain</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">47.3 (18.2)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–15.0 (–21.5 to –8.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">51.1 (16.2)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–20.2 (–26.8 to –13.6)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">5.3 (–3.9 to 14.4)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.91</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30.1 (23.7)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30.9 (21.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Total pain</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">45.1 (17.6)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–14.4 (–20.8 to –8.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">48.2 (14.7)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–19.4 (–25.2 to –13.6)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">5.0 (–3.6 to 13.5)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.91</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">28.2 (23.2)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">28.8 (21.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Medial JSW, mm</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">58</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.6 (1.2)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–0.0 (–0.1 to 0.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">52</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.6 (1.1)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–0.1 (–0.2 to 0.0)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">0.0 (–0.1 to 0.2)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.61</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">51</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.6 (1.2)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">48</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.5 (1.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Lateral JSW, mm</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">58</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.7 (1.4)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–0.2 (–0.3 to 0.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">52</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.8 (1.3)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">0.0 (–0.1 to 0.1)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–0.2 (–0.4 to 0.0)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.06</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">51</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.6 (1.5)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">48</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.7 (1.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Serum CTX-II, ng/mL</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.4 (0.5)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–0.1 (–0.3 to 0.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">62</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.5 (0.6)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–0.2 (–0.3 to –0.1)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">0.0 (–0.1 to 0.2)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.92</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.3 (0.5)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.4 (0.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Urine CTX-II, ng/mL</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">305.5 (208.3)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">37.8 (–20.3 to 95.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">62</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">300.1 (235.0)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–11.6 (–78.3 to 55.2)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">49.4 (–37.9 to 136.7)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.47</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">333.0 (266.8)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">309.1 (213.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Serum COMP, ng/mL</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1164.4 (647.9)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">10.0 (–66.5 to 86.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">62</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1078.5 (367.3)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">68.6 (–55.4 to 192.6)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–58.6 (–202.0 to 84.9)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.57</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1222.3 (748.4)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1149.0 (555.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Serum Coll2-1, pg/mL</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">483.5 (157.5)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">79.6 (34.2 to 124.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">62</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">505.0 (179.3)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">81.8 (45.3 to 118.3)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–2.2 (–59.7 to 55.3)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.80</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">561.8 (159.5)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">567.4 (233.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Serum Coll2-1 NO2, pg/mL</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">337.2 (158.8)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">112.3 (48.6 to 176.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">62</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">360.6 (269.0)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">136.2 (46.0 to 226.4)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–23.8 (–132.1 to 84.4)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.31</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">55</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">463.5 (298.3)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">494.7 (485.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Urine Coll2-1 NO2/creatinine normalized, nM</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">40.6 (26.1)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–14.4 (–20.8 to –8.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">62</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">41.8 (21.7)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">–19.4 (–25.2 to –13.6)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">5.0 (–3.6 to 13.5)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.63</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 48 wk</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">41.4 (23.1)</td>
                        <td valign="top" colspan="1" align="left" rowspan="1">54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">40.1 (23.5)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: Coll2-1, collagen II cleavage; Coll2-1 NO2, nitrated collagen II cleavage; COMP, cartilage oligomeric matrix protein; CTX-II, C-terminal telopeptide of collagen II; ICOAP, intermittent and constant pain; JSW, joint space width; NA, not applicable; OMERACT-OARSI, Outcome Measures in Rheumatology Clinical Trials–Osteoarthritis Research Society International; PLIUS, pulsed low-intensity ultrasonography; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.</p>
                    <fn id="zoi220042t2n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p><italic>P</italic> value determined from mixed-effects random intercept model, except where noted.</p>
                    </fn>
                    <fn id="zoi220042t2n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p><italic>P</italic> value determined from χ<sup>2</sup> test.</p>
                    </fn>
                    <fn id="zoi220042t2n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Higher values indicate more pain, stiffness, and functional limitations.</p>
                    </fn>
                    <fn id="zoi220042t2n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Measured on a visual analog scale (0-100) rated by patient or clinician for overall assessment of knee arthritis severity. Larger numbers indicate more severe conditions.</p>
                    </fn>
                    <fn id="zoi220042t2n5">
                      <label>
                        <sup>e</sup>
                      </label>
                      <p>Higher values indicate more severe conditions.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec id="H1-4-ZOI220042">
              <title>Discussion</title>
              <p>Despite its substantial morbidity, there are no disease-modifying therapies approved for knee OA by the US Food and Drug Administration. In 2021, 2 review articles highlighted the lack of effective interventions for disabling symptoms other than total joint replacement.<sup><xref rid="zoi220042r3" ref-type="bibr">3</xref>,<xref rid="zoi220042r8" ref-type="bibr">8</xref></sup> These facts provided the motivation for our trial of PLIUS in OA, together with promising in vitro and preclinical animal results.<sup><xref rid="zoi220042r19" ref-type="bibr">19</xref>,<xref rid="zoi220042r23" ref-type="bibr">23</xref></sup> We implemented therapy with a US Food and Drug Administration–approved ultrasonography device for fracture healing for which there is moderate- to high-quality evidence of efficacy as defined by reduced time to fracture union and improved quality of life.<sup><xref rid="zoi220042r49" ref-type="bibr">49</xref></sup> The selection of coprimary outcomes (OMERACT-OARSI and central medial femoral condyle cartilage thickness) for the present trial reflects the need for a clinically meaningful advance in OA treatment to both mitigate symptoms and lessen cartilage degeneration.</p>
              <p>In the present trial, neither coprimary outcome met its predefined threshold for benefit from PLIUS in treatment of knee OA. Symptomatic improvement occurred quickly in both the PLIUS and sham groups and was sustained for the duration of the study (eFigure in <xref rid="note-ZOI220042-1-s" ref-type="supplementary-material">Supplement 2</xref>); the percentage of OMERACT-OARSI responders was 70.4% in the PLIUS group and 67.3% in the sham group, consistent with other therapeutic trials that have used this outcome.<sup><xref rid="zoi220042r50" ref-type="bibr">50</xref></sup> Both groups experienced cartilage loss (range, 42.2-73.8 μm) at 48 weeks, similar to the previously reported annual loss of 47 μm.<sup><xref rid="zoi220042r37" ref-type="bibr">37</xref></sup></p>
              <p>Numerous secondary outcome measures were evaluated, including analgesia use as a potential signal of therapeutic response (eTable 1 and eTable 2 in <xref rid="note-ZOI220042-1-s" ref-type="supplementary-material">Supplement 2</xref>). Consistent with the coprimary outcome measures, no significant differences between treatment and sham groups were observed for any secondary outcome measure.</p>
              <p>The WOMAC score has been used extensively to quantify the symptoms of knee OA since its introduction in 1988.<sup><xref rid="zoi220042r31" ref-type="bibr">31</xref>,<xref rid="zoi220042r32" ref-type="bibr">32</xref></sup> Both the sham and PLIUS arms exhibited rapid and sustained improvements in the WOMAC pain, stiffness, and function subscales, which has been seen in other OA trials,<sup><xref rid="zoi220042r50" ref-type="bibr">50</xref>,<xref rid="zoi220042r51" ref-type="bibr">51</xref>,<xref rid="zoi220042r52" ref-type="bibr">52</xref></sup> and no significant differences between the 2 study arms were seen at any time in the trial. Increased WOMAC pain scores have been associated with increasing KLG in other OA populations,<sup><xref rid="zoi220042r53" ref-type="bibr">53</xref></sup> but an increase was not observed in our study cohort. The large placebo effect associated with both patient-reported and physician-reported subjective measures in randomized clinical trials of OA has been considered and presents a major limitation.<sup><xref rid="zoi220042r54" ref-type="bibr">54</xref>,<xref rid="zoi220042r55" ref-type="bibr">55</xref></sup></p>
              <p>Use of MRI in evaluation of cartilage in OA remains a rapidly evolving field, with the ability of MRI methods to accurately assess cartilage morphologic factors continuing to improve. Since the inception of this trial, there have been major advances in 3-dimensional morphological MRI of knee cartilage. It is likely that newer techniques, with scan times equivalent to those used in the present work, would yield lower measurement error in the assessment of the central medial femoral condyle cartilage thickness. Alternatively, a rapid imaging protocol with comparable image quality to that in the present study<sup><xref rid="zoi220042r56" ref-type="bibr">56</xref></sup> has been adopted in several ongoing clinical trials.<sup><xref rid="zoi220042r57" ref-type="bibr">57</xref></sup> New ultrahigh-resolution (0.3-mm isotropic) 3-dimensional morphological imaging techniques at ultrahigh field strength (7 T) are also showing promise for rapid measurement of cartilage morphometry. However, based on the large SD of our cartilage thickness measurements, we recommend that the emphasis in future studies be placed on accuracy and precision, rather than measurement speed. In any event, these continuing advances in MRI methods have the potential to quantify OA therapeutics in a manner that is both sensitive and cost-effective.</p>
              <p>We monitored serial serum and urine biomarkers of OA to evaluate the efficacy and time course of therapeutic response to PLIUS.<sup><xref rid="zoi220042r44" ref-type="bibr">44</xref>,<xref rid="zoi220042r58" ref-type="bibr">58</xref>,<xref rid="zoi220042r59" ref-type="bibr">59</xref></sup> Despite the wide range of biomarkers studied, no biochemical signal of therapeutic response was observed. This includes lack of a treatment effect in urinary C-terminal telopeptide of collagen II, which has been proposed as a predictor of radiographic change.<sup><xref rid="zoi220042r58" ref-type="bibr">58</xref></sup> We did not incorporate markers of synovial or bone response or of inflammation.<sup><xref rid="zoi220042r58" ref-type="bibr">58</xref></sup> Given the null results, no determination of biomarker sensitivity or positive predictive value was possible.<sup><xref rid="zoi220042r51" ref-type="bibr">51</xref></sup> Although changes from baseline to 48 weeks were seen in most outcomes, there were no statistically significant differences between groups for any of the outcomes consistent with the primary outcome results.</p>
              <sec id="H2-10-ZOI220042">
                <title>Limitations</title>
                <p>This study has limitations. Among the study’s limitations were barriers to recruitment, including primarily failure to meet KLG and WOMAC pain scores for entry. The study participants were drawn from a population receiving care through the VA, and as expected, most were men. Thus, the results may not be generalizable to the overall OA population. Subgroup analysis of men and women was not performed. We are not aware of sex differences reported in other studies of PLIUS. Accordingly, we believe that it is unlikely that results would differ in a female population. Furthermore, although adherence to device administration was excellent according to the criteria monitored by the device itself (&gt;90%), adequacy of device placement could not be assessed. In addition, many challenges in the quantification of OA symptoms remain, including the placebo effects discussed. Although the placebo effects can be addressed through use of double-blind, placebo-controlled randomized clinical trial methods, ceiling and floor effects, as well as a much-narrowed dynamic range of outcomes, remain as substantial problems. In addition, our application of PLIUS was based primarily on its successful use in fracture healing. However, it is clear that optimal ultrasonographic parameters for cartilage repair may vary substantially from those that are effective for fracture healing.<sup><xref rid="zoi220042r60" ref-type="bibr">60</xref>,<xref rid="zoi220042r61" ref-type="bibr">61</xref>,<xref rid="zoi220042r62" ref-type="bibr">62</xref></sup> For example, our dosage was approximately 1% to 5% of that used by Loyola-Sánchez et al.<sup><xref rid="zoi220042r27" ref-type="bibr">27</xref></sup> We believe that this topic merits further study, given the documented anabolic effects of PLIUS for cartilage matrix in vitro and in preclinical animal studies and the current lack of any disease-modifying therapeutics for OA.</p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI220042">
              <title>Conclusions</title>
              <p>Although PLIUS benefit was not observed and promising signals for future investigation were not immediately apparent, this clinical trial provides subjective, objective (joint space width by radiographic and cartilage thickening by MRI), and biomarker information. This information may aid future trial design by better defining expected ranges of values and rates of change. No signal was identified in this 48-week trial to suggest that PLIUS, applied as described, provides benefit for either OA symptoms or cartilage loss in knee OA.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI220042">
              <title>References</title>
              <ref id="zoi220042r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kotlarz</surname><given-names>H</given-names></string-name>, <string-name><surname>Gunnarsson</surname><given-names>CL</given-names></string-name>, <string-name><surname>Fang</surname><given-names>H</given-names></string-name>, <string-name><surname>Rizzo</surname><given-names>JA</given-names></string-name></person-group>. <article-title>Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data</article-title>. <source>Arthritis Rheum</source>. <year>2009</year>;<volume>60</volume>(<issue>12</issue>):<fpage>3546</fpage>-<lpage>3553</lpage>. doi:<pub-id pub-id-type="doi">10.1002/art.24984</pub-id><?supplied-pmid 19950287?><pub-id pub-id-type="pmid">19950287</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Runhaar</surname><given-names>J</given-names></string-name>, <string-name><surname>Schiphof</surname><given-names>D</given-names></string-name>, <string-name><surname>van Meer</surname><given-names>B</given-names></string-name>, <string-name><surname>Reijman</surname><given-names>M</given-names></string-name>, <string-name><surname>Bierma-Zeinstra</surname><given-names>SM</given-names></string-name>, <string-name><surname>Oei</surname><given-names>EH</given-names></string-name></person-group>. <article-title>How to define subregional osteoarthritis progression using semi-quantitative MRI osteoarthritis knee score (MOAKS)</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2014</year>;<volume>22</volume>(<issue>10</issue>):<fpage>1533</fpage>-<lpage>1536</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2014.06.022</pub-id><?supplied-pmid 25278062?><pub-id pub-id-type="pmid">25278062</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Katz</surname><given-names>JN</given-names></string-name>, <string-name><surname>Arant</surname><given-names>KR</given-names></string-name>, <string-name><surname>Loeser</surname><given-names>RF</given-names></string-name></person-group>. <article-title>Diagnosis and treatment of hip and knee osteoarthritis: a review</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>325</volume>(<issue>6</issue>):<fpage>568</fpage>-<lpage>578</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.22171</pub-id><?supplied-pmid 33560326?><pub-id pub-id-type="pmid">33560326</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Weinstein</surname><given-names>AM</given-names></string-name>, <string-name><surname>Rome</surname><given-names>BN</given-names></string-name>, <string-name><surname>Reichmann</surname><given-names>WM</given-names></string-name>, <etal/></person-group>. <article-title>Estimating the burden of total knee replacement in the United States</article-title>. <source>J Bone Joint Surg Am</source>. <year>2013</year>;<volume>95</volume>(<issue>5</issue>):<fpage>385</fpage>-<lpage>392</lpage>. doi:<pub-id pub-id-type="doi">10.2106/JBJS.L.00206</pub-id><?supplied-pmid 23344005?><pub-id pub-id-type="pmid">23344005</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hootman</surname><given-names>JM</given-names></string-name>, <string-name><surname>Helmick</surname><given-names>CG</given-names></string-name></person-group>. <article-title>Projections of US prevalence of arthritis and associated activity limitations</article-title>. <source>Arthritis Rheum</source>. <year>2006</year>;<volume>54</volume>(<issue>1</issue>):<fpage>226</fpage>-<lpage>229</lpage>. doi:<pub-id pub-id-type="doi">10.1002/art.21562</pub-id><?supplied-pmid 16385518?><pub-id pub-id-type="pmid">16385518</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Roos</surname><given-names>EM</given-names></string-name>, <string-name><surname>Arden</surname><given-names>NK</given-names></string-name></person-group>. <article-title>Strategies for the prevention of knee osteoarthritis</article-title>. <source>Nat Rev Rheumatol</source>. <year>2016</year>;<volume>12</volume>(<issue>2</issue>):<fpage>92</fpage>-<lpage>101</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrrheum.2015.135</pub-id><?supplied-pmid 26439406?><pub-id pub-id-type="pmid">26439406</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cameron</surname><given-names>KL</given-names></string-name>, <string-name><surname>Hsiao</surname><given-names>MS</given-names></string-name>, <string-name><surname>Owens</surname><given-names>BD</given-names></string-name>, <string-name><surname>Burks</surname><given-names>R</given-names></string-name>, <string-name><surname>Svoboda</surname><given-names>SJ</given-names></string-name></person-group>. <article-title>Incidence of physician-diagnosed osteoarthritis among active duty United States military service members</article-title>. <source>Arthritis Rheum</source>. <year>2011</year>;<volume>63</volume>(<issue>10</issue>):<fpage>2974</fpage>-<lpage>2982</lpage>. doi:<pub-id pub-id-type="doi">10.1002/art.30498</pub-id><?supplied-pmid 21717422?><pub-id pub-id-type="pmid">21717422</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sharma</surname><given-names>L</given-names></string-name></person-group>. <article-title>Osteoarthritis of the knee</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>(<issue>1</issue>):<fpage>51</fpage>-<lpage>59</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMcp1903768</pub-id><?supplied-pmid 33406330?><pub-id pub-id-type="pmid">33406330</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kuo</surname><given-names>AC</given-names></string-name>, <string-name><surname>Rodrigo</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Reddi</surname><given-names>AH</given-names></string-name>, <string-name><surname>Curtiss</surname><given-names>S</given-names></string-name>, <string-name><surname>Grotkopp</surname><given-names>E</given-names></string-name>, <string-name><surname>Chiu</surname><given-names>M</given-names></string-name></person-group>. <article-title>Microfracture and bone morphogenetic protein 7 (BMP-7) synergistically stimulate articular cartilage repair</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2006</year>;<volume>14</volume>(<issue>11</issue>):<fpage>1126</fpage>-<lpage>1135</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2006.04.004</pub-id><?supplied-pmid 16765606?><pub-id pub-id-type="pmid">16765606</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Malinin</surname><given-names>T</given-names></string-name>, <string-name><surname>Temple</surname><given-names>HT</given-names></string-name>, <string-name><surname>Buck</surname><given-names>BE</given-names></string-name></person-group>. <article-title>Transplantation of osteochondral allografts after cold storage</article-title>. <source>J Bone Joint Surg Am</source>. <year>2006</year>;<volume>88</volume>(<issue>4</issue>):<fpage>762</fpage>-<lpage>770</lpage>. doi:<pub-id pub-id-type="doi">10.2106/JBJS.D.02991</pub-id><?supplied-pmid 16595466?><pub-id pub-id-type="pmid">16595466</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Wasiak</surname><given-names>J</given-names></string-name>, <string-name><surname>Clar</surname><given-names>C</given-names></string-name>, <string-name><surname>Villanueva</surname><given-names>E</given-names></string-name></person-group>. <article-title>Autologous cartilage implantation for full thickness articular cartilage defects of the knee</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2006</year>;(<issue>3</issue>):<elocation-id>CD003323</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD003323.pub2</pub-id><?supplied-pmid 16856003?><pub-id pub-id-type="pmid">16856003</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nolte</surname><given-names>PA</given-names></string-name>, <string-name><surname>van der Krans</surname><given-names>A</given-names></string-name>, <string-name><surname>Patka</surname><given-names>P</given-names></string-name>, <string-name><surname>Janssen</surname><given-names>IM</given-names></string-name>, <string-name><surname>Ryaby</surname><given-names>JP</given-names></string-name>, <string-name><surname>Albers</surname><given-names>GH</given-names></string-name></person-group>. <article-title>Low-intensity pulsed ultrasound in the treatment of nonunions</article-title>. <source>J Trauma</source>. <year>2001</year>;<volume>51</volume>(<issue>4</issue>):<fpage>693</fpage>-<lpage>702</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00005373-200110000-00012</pub-id><?supplied-pmid 11586161?><pub-id pub-id-type="pmid">11586161</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Leung</surname><given-names>KS</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>WH</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name><surname>Lee</surname><given-names>KM</given-names></string-name>, <string-name><surname>Lo</surname><given-names>HK</given-names></string-name></person-group>. <article-title>Low intensity pulsed ultrasound stimulates osteogenic activity of human periosteal cells</article-title>. <source>Clin Orthop Relat Res</source>. <year>2004</year>;(<issue>418</issue>):<fpage>253</fpage>-<lpage>259</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00003086-200401000-00044</pub-id><?supplied-pmid 15043127?><pub-id pub-id-type="pmid">15043127</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Grodzinsky</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Levenston</surname><given-names>ME</given-names></string-name>, <string-name><surname>Jin</surname><given-names>M</given-names></string-name>, <string-name><surname>Frank</surname><given-names>EH</given-names></string-name></person-group>. <article-title>Cartilage tissue remodeling in response to mechanical forces</article-title>. <source>Annu Rev Biomed Eng</source>. <year>2000</year>;<volume>2</volume>:<fpage>691</fpage>-<lpage>713</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev.bioeng.2.1.691</pub-id><?supplied-pmid 11701528?><pub-id pub-id-type="pmid">11701528</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Heath</surname><given-names>CA</given-names></string-name>, <string-name><surname>Magari</surname><given-names>SR</given-names></string-name></person-group>. <article-title>Mini-review: mechanical factors affecting cartilage regeneration in vitro</article-title>. <source>Biotechnol Bioeng</source>. <year>1996</year>;<volume>50</volume>(<issue>4</issue>):<fpage>430</fpage>-<lpage>437</lpage>. doi:<pub-id pub-id-type="doi">10.1002/(SICI)1097-0290(19960520)50:4&lt;430::AID-BIT10&gt;3.0.CO;2-N</pub-id><?supplied-pmid 18626992?><pub-id pub-id-type="pmid">18626992</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Naito</surname><given-names>K</given-names></string-name>, <string-name><surname>Watari</surname><given-names>T</given-names></string-name>, <string-name><surname>Muta</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Low-intensity pulsed ultrasound (LIPUS) increases the articular cartilage type II collagen in a rat osteoarthritis model</article-title>. <source>J Orthop Res</source>. <year>2010</year>;<volume>28</volume>(<issue>3</issue>):<fpage>361</fpage>-<lpage>369</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jor.20995</pub-id><?supplied-pmid 19810106?><pub-id pub-id-type="pmid">19810106</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Zhang</surname><given-names>Zi</given-names></string-name>, <string-name><surname>Huckle</surname><given-names>J</given-names></string-name>, <string-name><surname>Francomano</surname><given-names>CA</given-names></string-name>, <string-name><surname>Spencer</surname><given-names>RG</given-names></string-name></person-group>. <article-title>The influence of pulsed low-intensity ultrasound on matrix production of chondrocytes at different stages of differentiation: an explant study</article-title>. <source>Ultrasound Med Biol</source>. <year>2002</year>;<volume>28</volume>(<issue>11-12</issue>):<fpage>1547</fpage>-<lpage>1553</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0301-5629(02)00659-2</pub-id><?supplied-pmid 12498950?><pub-id pub-id-type="pmid">12498950</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Zhang</surname><given-names>ZJ</given-names></string-name>, <string-name><surname>Huckle</surname><given-names>J</given-names></string-name>, <string-name><surname>Francomano</surname><given-names>CA</given-names></string-name>, <string-name><surname>Spencer</surname><given-names>RG</given-names></string-name></person-group>. <article-title>The effects of pulsed low-intensity ultrasound on chondrocyte viability, proliferation, gene expression and matrix production</article-title>. <source>Ultrasound Med Biol</source>. <year>2003</year>;<volume>29</volume>(<issue>11</issue>):<fpage>1645</fpage>-<lpage>1651</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ultrasmedbio.2003.08.011</pub-id><?supplied-pmid 14654159?><pub-id pub-id-type="pmid">14654159</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cook</surname><given-names>SD</given-names></string-name>, <string-name><surname>Salkeld</surname><given-names>SL</given-names></string-name>, <string-name><surname>Popich-Patron</surname><given-names>LS</given-names></string-name>, <string-name><surname>Ryaby</surname><given-names>JP</given-names></string-name>, <string-name><surname>Jones</surname><given-names>DG</given-names></string-name>, <string-name><surname>Barrack</surname><given-names>RL</given-names></string-name></person-group>. <article-title>Improved cartilage repair after treatment with low-intensity pulsed ultrasound</article-title>. <source>Clin Orthop Relat Res</source>. <year>2001</year>;(<issue>391</issue>)(<supplement>suppl</supplement>):<fpage>S231</fpage>-<lpage>S243</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00003086-200110001-00022</pub-id><?supplied-pmid 11603707?><pub-id pub-id-type="pmid">11603707</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Xia</surname><given-names>P</given-names></string-name>, <string-name><surname>Shen</surname><given-names>S</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>Low-intensity pulsed ultrasound treatment at an early osteoarthritis stage protects rabbit cartilage from damage via the integrin/focal adhesion kinase/mitogen-activated protein kinase signaling pathway</article-title>. <source>J Ultrasound Med</source>. <year>2015</year>;<volume>34</volume>(<issue>11</issue>):<fpage>1991</fpage>-<lpage>1999</lpage>. doi:<pub-id pub-id-type="doi">10.7863/ultra.14.10016</pub-id><?supplied-pmid 26396170?><pub-id pub-id-type="pmid">26396170</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nishida</surname><given-names>T</given-names></string-name>, <string-name><surname>Kubota</surname><given-names>S</given-names></string-name>, <string-name><surname>Aoyama</surname><given-names>E</given-names></string-name>, <string-name><surname>Yamanaka</surname><given-names>N</given-names></string-name>, <string-name><surname>Lyons</surname><given-names>KM</given-names></string-name>, <string-name><surname>Takigawa</surname><given-names>M</given-names></string-name></person-group>. <article-title>Low-intensity pulsed ultrasound (LIPUS) treatment of cultured chondrocytes stimulates production of CCN family protein 2 (CCN2), a protein involved in the regeneration of articular cartilage: mechanism underlying this stimulation</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2017</year>;<volume>25</volume>(<issue>5</issue>):<fpage>759</fpage>-<lpage>769</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2016.10.003</pub-id><?supplied-pmid 27729291?><pub-id pub-id-type="pmid">27729291</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Altman</surname><given-names>RD</given-names></string-name>, <string-name><surname>Bloch</surname><given-names>DA</given-names></string-name>, <string-name><surname>Bole</surname><given-names>GG</given-names><suffix>Jr</suffix></string-name>, <etal/></person-group>. <article-title>Development of clinical criteria for osteoarthritis</article-title>. <source>J Rheumatol</source>. <year>1987</year>;<volume>14</volume>(<issue>Spec No</issue>):<fpage>3</fpage>-<lpage>6</lpage>.<?supplied-pmid 3625674?><pub-id pub-id-type="pmid">3625674</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gurkan</surname><given-names>I</given-names></string-name>, <string-name><surname>Ranganathan</surname><given-names>A</given-names></string-name>, <string-name><surname>Yang</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Modification of osteoarthritis in the guinea pig with pulsed low-intensity ultrasound treatment</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2010</year>;<volume>18</volume>(<issue>5</issue>):<fpage>724</fpage>-<lpage>733</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2010.01.006</pub-id><?supplied-pmid 20175971?><pub-id pub-id-type="pmid">20175971</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Draper</surname><given-names>DO</given-names></string-name>, <string-name><surname>Klyve</surname><given-names>D</given-names></string-name>, <string-name><surname>Ortiz</surname><given-names>R</given-names></string-name>, <string-name><surname>Best</surname><given-names>TM</given-names></string-name></person-group>. <article-title>Effect of low-intensity long-duration ultrasound on the symptomatic relief of knee osteoarthritis: a randomized, placebo-controlled double-blind study</article-title>. <source>J Orthop Surg Res</source>. <year>2018</year>;<volume>13</volume>(<issue>1</issue>):<fpage>257</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13018-018-0965-0</pub-id><?supplied-pmid 30326947?><pub-id pub-id-type="pmid">30326947</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Jia</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name><surname>Chen</surname><given-names>W</given-names></string-name></person-group>. <article-title>Efficacy of focused low-intensity pulsed ultrasound therapy for the management of knee osteoarthritis: a randomized, double blind, placebo-controlled trial</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>35453</fpage>. doi:<pub-id pub-id-type="doi">10.1038/srep35453</pub-id><?supplied-pmid 27748432?><pub-id pub-id-type="pmid">27748432</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Loyola Sánchez</surname><given-names>A</given-names></string-name>, <string-name><surname>Ramirez Wakamatzu</surname><given-names>MA</given-names></string-name>, <string-name><surname>Vazquez Zamudio</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>[Effect of low-intensity pulsed ultrasound on regeneration of joint cartilage in patients with second and third degree osteoarthritis of the knee]</article-title> [Spanish]. <source>Reumatol Clin</source>. <year>2009</year>;<volume>5</volume>(<issue>4</issue>):<fpage>163</fpage>-<lpage>167</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2173-5743(09)70113-3</pub-id><?supplied-pmid 21794602?><pub-id pub-id-type="pmid">21794602</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Loyola-Sánchez</surname><given-names>A</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>J</given-names></string-name>, <string-name><surname>Beattie</surname><given-names>KA</given-names></string-name>, <string-name><surname>Otero-Fuentes</surname><given-names>C</given-names></string-name>, <string-name><surname>Adachi</surname><given-names>JD</given-names></string-name>, <string-name><surname>MacIntyre</surname><given-names>NJ</given-names></string-name></person-group>. <article-title>Effect of low-intensity pulsed ultrasound on the cartilage repair in people with mild to moderate knee osteoarthritis: a double-blinded, randomized, placebo-controlled pilot study</article-title>. <source>Arch Phys Med Rehabil</source>. <year>2012</year>;<volume>93</volume>(<issue>1</issue>):<fpage>35</fpage>-<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.apmr.2011.07.196</pub-id><?supplied-pmid 22200383?><pub-id pub-id-type="pmid">22200383</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Rothenberg</surname><given-names>JB</given-names></string-name>, <string-name><surname>Jayaram</surname><given-names>P</given-names></string-name>, <string-name><surname>Naqvi</surname><given-names>U</given-names></string-name>, <string-name><surname>Gober</surname><given-names>J</given-names></string-name>, <string-name><surname>Malanga</surname><given-names>GA</given-names></string-name></person-group>. <article-title>The role of low-intensity pulsed ultrasound on cartilage healing in knee osteoarthritis: a review</article-title>. <source>PM R</source>. <year>2017</year>;<volume>9</volume>(<issue>12</issue>):<fpage>1268</fpage>-<lpage>1277</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pmrj.2017.05.008</pub-id><?supplied-pmid 28606838?><pub-id pub-id-type="pmid">28606838</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Zhou</surname><given-names>XY</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>XX</given-names></string-name>, <string-name><surname>Yu</surname><given-names>GY</given-names></string-name>, <etal/></person-group>. <article-title>Effects of low-intensity pulsed ultrasound on knee osteoarthritis: a meta-analysis of randomized clinical trials</article-title>. <source>Biomed Res Int</source>. <year>2018</year>;<volume>2018</volume>:<elocation-id>7469197</elocation-id>. doi:<pub-id pub-id-type="doi">10.1155/2018/7469197</pub-id><?supplied-pmid 30105243?><pub-id pub-id-type="pmid">30105243</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kellgren</surname><given-names>JH</given-names></string-name>, <string-name><surname>Lawrence</surname><given-names>JS</given-names></string-name></person-group>. <article-title>Radiological assessment of osteo-arthrosis</article-title>. <source>Ann Rheum Dis</source>. <year>1957</year>;<volume>16</volume>(<issue>4</issue>):<fpage>494</fpage>-<lpage>502</lpage>. doi:<pub-id pub-id-type="doi">10.1136/ard.16.4.494</pub-id><?supplied-pmid 13498604?><pub-id pub-id-type="pmid">13498604</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bellamy</surname><given-names>N</given-names></string-name></person-group>. <article-title>Pain assessment in osteoarthritis: experience with the WOMAC osteoarthritis index</article-title>. <source>Semin Arthritis Rheum</source>. <year>1989</year>;<volume>18</volume>(<issue>4</issue>)(<supplement>suppl 2</supplement>):<fpage>14</fpage>-<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0049-0172(89)90010-3</pub-id><?supplied-pmid 2786253?><pub-id pub-id-type="pmid">2786253</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bellamy</surname><given-names>N</given-names></string-name>, <string-name><surname>Buchanan</surname><given-names>WW</given-names></string-name>, <string-name><surname>Goldsmith</surname><given-names>CH</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>J</given-names></string-name>, <string-name><surname>Stitt</surname><given-names>LW</given-names></string-name></person-group>. <article-title>Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee</article-title>. <source>J Rheumatol</source>. <year>1988</year>;<volume>15</volume>(<issue>12</issue>):<fpage>1833</fpage>-<lpage>1840</lpage>.<?supplied-pmid 3068365?><pub-id pub-id-type="pmid">3068365</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hochberg</surname><given-names>MC</given-names></string-name>, <string-name><surname>Chang</surname><given-names>RW</given-names></string-name>, <string-name><surname>Dwosh</surname><given-names>I</given-names></string-name>, <string-name><surname>Lindsey</surname><given-names>S</given-names></string-name>, <string-name><surname>Pincus</surname><given-names>T</given-names></string-name>, <string-name><surname>Wolfe</surname><given-names>F</given-names></string-name></person-group>. <article-title>The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source>. <year>1992</year>;<volume>35</volume>(<issue>5</issue>):<fpage>498</fpage>-<lpage>502</lpage>. doi:<pub-id pub-id-type="doi">10.1002/art.1780350502</pub-id><?supplied-pmid 1575785?><pub-id pub-id-type="pmid">1575785</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Schulz</surname><given-names>KF</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name><surname>Moher</surname><given-names>D</given-names></string-name>; <collab>CONSORT Group</collab></person-group>. <article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials</article-title>. <source>Ann Intern Med</source>. <year>2010</year>;<volume>152</volume>(<issue>11</issue>):<fpage>726</fpage>-<lpage>732</lpage>. doi:<pub-id pub-id-type="doi">10.7326/0003-4819-152-11-201006010-00232</pub-id><?supplied-pmid 20335313?><pub-id pub-id-type="pmid">20335313</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Eldridge</surname><given-names>SM</given-names></string-name>, <string-name><surname>Chan</surname><given-names>CL</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>MJ</given-names></string-name>, <etal/>; <collab>PAFS consensus group</collab></person-group>. <article-title>CONSORT 2010 statement: extension to randomised pilot and feasibility trials</article-title>. <source>BMJ</source>. <year>2016</year>;<volume>355</volume>:<fpage>i5239</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.i5239</pub-id><?supplied-pmid 27777223?><pub-id pub-id-type="pmid">27777223</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Pham</surname><given-names>T</given-names></string-name>, <string-name><surname>van der Heijde</surname><given-names>D</given-names></string-name>, <string-name><surname>Altman</surname><given-names>RD</given-names></string-name>, <etal/></person-group>. <article-title>OMERACT-OARSI initiative: Osteoarthritis Research Society international set of responder criteria for osteoarthritis clinical trials revisited</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2004</year>;<volume>12</volume>(<issue>5</issue>):<fpage>389</fpage>-<lpage>399</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2004.02.001</pub-id><?supplied-pmid 15094138?><pub-id pub-id-type="pmid">15094138</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Wirth</surname><given-names>W</given-names></string-name>, <string-name><surname>Larroque</surname><given-names>S</given-names></string-name>, <string-name><surname>Davies</surname><given-names>RY</given-names></string-name>, <etal/>; <collab>OA Initiative Investigators Group</collab></person-group>. <article-title>Comparison of 1-year vs 2-year change in regional cartilage thickness in osteoarthritis results from 346 participants from the Osteoarthritis Initiative</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2011</year>;<volume>19</volume>(<issue>1</issue>):<fpage>74</fpage>-<lpage>83</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2010.10.022</pub-id><?supplied-pmid 21044690?><pub-id pub-id-type="pmid">21044690</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hunter</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Altman</surname><given-names>RD</given-names></string-name>, <string-name><surname>Cicuttini</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>OARSI clinical trials recommendations: knee imaging in clinical trials in osteoarthritis</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2015</year>;<volume>23</volume>(<issue>5</issue>):<fpage>698</fpage>-<lpage>715</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2015.03.012</pub-id><?supplied-pmid 25952343?><pub-id pub-id-type="pmid">25952343</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hunter</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name><surname>Conaghan</surname><given-names>PG</given-names></string-name>, <etal/></person-group>. <article-title>Responsiveness and reliability of MRI in knee osteoarthritis: a meta-analysis of published evidence</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2011</year>;<volume>19</volume>(<issue>5</issue>):<fpage>589</fpage>-<lpage>605</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2010.10.030</pub-id><?supplied-pmid 21396465?><pub-id pub-id-type="pmid">21396465</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Wirth</surname><given-names>W</given-names></string-name>, <string-name><surname>Duryea</surname><given-names>J</given-names></string-name>, <string-name><surname>Hellio Le Graverand</surname><given-names>MP</given-names></string-name>, <etal/>; <collab>OA Initiative Investigators Group</collab></person-group>. <article-title>Direct comparison of fixed flexion, radiography and MRI in knee osteoarthritis: responsiveness data from the Osteoarthritis Initiative</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2013</year>;<volume>21</volume>(<issue>1</issue>):<fpage>117</fpage>-<lpage>125</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2012.10.017</pub-id><?supplied-pmid 23128183?><pub-id pub-id-type="pmid">23128183</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Wirth</surname><given-names>W</given-names></string-name>, <string-name><surname>Eckstein</surname><given-names>F</given-names></string-name></person-group>. <article-title>A technique for regional analysis of femorotibial cartilage thickness based on quantitative magnetic resonance imaging</article-title>. <source>IEEE Trans Med Imaging</source>. <year>2008</year>;<volume>27</volume>(<issue>6</issue>):<fpage>737</fpage>-<lpage>744</lpage>. doi:<pub-id pub-id-type="doi">10.1109/TMI.2007.907323</pub-id><?supplied-pmid 18541481?><pub-id pub-id-type="pmid">18541481</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hochberg</surname><given-names>MC</given-names></string-name>, <string-name><surname>Altman</surname><given-names>RD</given-names></string-name>, <string-name><surname>Brandt</surname><given-names>KD</given-names></string-name>, <string-name><surname>Moskowitz</surname><given-names>RW</given-names></string-name></person-group>. <article-title>Design and conduct of clinical trials in osteoarthritis: preliminary recommendations from a task force of the Osteoarthritis Research Society</article-title>. <source>J Rheumatol</source>. <year>1997</year>;<volume>24</volume>(<issue>4</issue>):<fpage>792</fpage>-<lpage>794</lpage>.<?supplied-pmid 9101520?><pub-id pub-id-type="pmid">9101520</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hawker</surname><given-names>GA</given-names></string-name>, <string-name><surname>Mian</surname><given-names>S</given-names></string-name>, <string-name><surname>Kendzerska</surname><given-names>T</given-names></string-name>, <string-name><surname>French</surname><given-names>M</given-names></string-name></person-group>. <article-title>Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill Pain Questionnaire (MPQ), Short-form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short form-36 Bodily Pain Scale (SF-36 BPS), and measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)</article-title>. <source>Arthritis Care Res (Hoboken)</source>. <year>2011</year>;<volume>63</volume>(<issue>suppl 11</issue>):<fpage>S240</fpage>-<lpage>S252</lpage>. doi:<pub-id pub-id-type="doi">10.1002/acr.20543</pub-id><?supplied-pmid 22588748?><pub-id pub-id-type="pmid">22588748</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kraus</surname><given-names>VB</given-names></string-name>, <string-name><surname>Collins</surname><given-names>JE</given-names></string-name>, <string-name><surname>Hargrove</surname><given-names>D</given-names></string-name>, <etal/>; <collab>OA Biomarkers Consortium</collab></person-group>. <article-title>Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium</article-title>. <source>Ann Rheum Dis</source>. <year>2017</year>;<volume>76</volume>(<issue>1</issue>):<fpage>186</fpage>-<lpage>195</lpage>. doi:<pub-id pub-id-type="doi">10.1136/annrheumdis-2016-209252</pub-id><?supplied-pmid 27296323?><pub-id pub-id-type="pmid">27296323</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r45">
                <label>45</label>
                <mixed-citation publication-type="webpage">Exogen <year>2000</year> summary of safety and effectiveness. Accessed 2014. <ext-link xlink:href="https://www.accessdata.fda.gov/cdrh_docs/pdf/P900009S006b.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/cdrh_docs/pdf/P900009S006b.pdf</ext-link></mixed-citation>
              </ref>
              <ref id="zoi220042r46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Simon</surname><given-names>R</given-names></string-name>, <string-name><surname>Wittes</surname><given-names>RE</given-names></string-name>, <string-name><surname>Ellenberg</surname><given-names>SS</given-names></string-name></person-group>. <article-title>Randomized phase II clinical trials</article-title>. <source>Cancer Treat Rep</source>. <year>1985</year>;<volume>69</volume>(<issue>12</issue>):<fpage>1375</fpage>-<lpage>1381</lpage>.<?supplied-pmid 4075313?><pub-id pub-id-type="pmid">4075313</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r47">
                <label>47</label>
                <mixed-citation publication-type="book"><person-group><string-name><surname>Gibbons</surname><given-names>J</given-names></string-name>, <string-name><surname>Olkin</surname><given-names>I</given-names></string-name>, <string-name><surname>Sobel</surname><given-names>M.</given-names></string-name></person-group><source>Selecting and Ordering Populations: A New Statistical Methodology.</source><publisher-name>John Wiley &amp; Sons</publisher-name>; <year>1977</year>.</mixed-citation>
              </ref>
              <ref id="zoi220042r48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gibbons</surname><given-names>J</given-names></string-name>, <string-name><surname>Olkin</surname><given-names>I</given-names></string-name>, <string-name><surname>Sobel</surname><given-names>M.</given-names></string-name></person-group><article-title>Introduction to ranking and selection</article-title>. <source>American Statistician.</source><year>1979</year>;<volume>33</volume>(<issue>4</issue>):<fpage>185</fpage>-<lpage>195</lpage>.</mixed-citation>
              </ref>
              <ref id="zoi220042r49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lou</surname><given-names>S</given-names></string-name>, <string-name><surname>Lv</surname><given-names>H</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name><surname>Tang</surname><given-names>P</given-names></string-name></person-group>. <article-title>The effects of low-intensity pulsed ultrasound on fresh fracture: a meta-analysis</article-title>. <source>Medicine (Baltimore)</source>. <year>2017</year>;<volume>96</volume>(<issue>39</issue>):<elocation-id>e8181</elocation-id>. doi:<pub-id pub-id-type="doi">10.1097/MD.0000000000008181</pub-id><?supplied-pmid 28953676?><pub-id pub-id-type="pmid">28953676</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r50">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Clegg</surname><given-names>DO</given-names></string-name>, <string-name><surname>Reda</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Harris</surname><given-names>CL</given-names></string-name>, <etal/></person-group>. <article-title>Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>354</volume>(<issue>8</issue>):<fpage>795</fpage>-<lpage>808</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa052771</pub-id><?supplied-pmid 16495392?><pub-id pub-id-type="pmid">16495392</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>van Spil</surname><given-names>WE</given-names></string-name>, <string-name><surname>DeGroot</surname><given-names>J</given-names></string-name>, <string-name><surname>Lems</surname><given-names>WF</given-names></string-name>, <string-name><surname>Oostveen</surname><given-names>JC</given-names></string-name>, <string-name><surname>Lafeber</surname><given-names>FP</given-names></string-name></person-group>. <article-title>Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2010</year>;<volume>18</volume>(<issue>5</issue>):<fpage>605</fpage>-<lpage>612</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2010.01.012</pub-id><?supplied-pmid 20175979?><pub-id pub-id-type="pmid">20175979</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hochberg</surname><given-names>MC</given-names></string-name>, <string-name><surname>Martel-Pelletier</surname><given-names>J</given-names></string-name>, <string-name><surname>Monfort</surname><given-names>J</given-names></string-name>, <etal/>; <collab>MOVES Investigation Group</collab></person-group>. <article-title>Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib</article-title>. <source>Ann Rheum Dis</source>. <year>2016</year>;<volume>75</volume>(<issue>1</issue>):<fpage>37</fpage>-<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.1136/annrheumdis-2014-206792</pub-id><?supplied-pmid 25589511?><pub-id pub-id-type="pmid">25589511</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r53">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Neogi</surname><given-names>T</given-names></string-name>, <string-name><surname>Felson</surname><given-names>D</given-names></string-name>, <string-name><surname>Niu</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies</article-title>. <source>BMJ</source>. <year>2009</year>;<volume>339</volume>:<fpage>b2844</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.b2844</pub-id><?supplied-pmid 19700505?><pub-id pub-id-type="pmid">19700505</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r54">
                <label>54</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Zhang</surname><given-names>W</given-names></string-name></person-group>. <article-title>The powerful placebo effect in osteoarthritis</article-title>. <source>Clin Exp Rheumatol</source>. <year>2019</year>;<volume>37</volume>(<issue>5</issue>)(<supplement>suppl 120</supplement>):<fpage>118</fpage>-<lpage>123</lpage>.<?supplied-pmid 31621561?><pub-id pub-id-type="pmid">31621561</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r55">
                <label>55</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chen</surname><given-names>AT</given-names></string-name>, <string-name><surname>Shrestha</surname><given-names>S</given-names></string-name>, <string-name><surname>Collins</surname><given-names>JE</given-names></string-name>, <string-name><surname>Sullivan</surname><given-names>JK</given-names></string-name>, <string-name><surname>Losina</surname><given-names>E</given-names></string-name>, <string-name><surname>Katz</surname><given-names>JN</given-names></string-name></person-group>. <article-title>Estimating contextual effect in nonpharmacological therapies for pain in knee osteoarthritis: a systematic analytic review</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2020</year>;<volume>28</volume>(<issue>9</issue>):<fpage>1154</fpage>-<lpage>1169</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2020.05.007</pub-id><?supplied-pmid 32416220?><pub-id pub-id-type="pmid">32416220</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r56">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chaudhari</surname><given-names>AS</given-names></string-name>, <string-name><surname>Black</surname><given-names>MS</given-names></string-name>, <string-name><surname>Eijgenraam</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Five-minute knee MRI for simultaneous morphometry and T<sub>2</sub> relaxometry of cartilage and meniscus and for semiquantitative radiological assessment using double-echo in steady-state at 3T</article-title>. <source>J Magn Reson Imaging</source>. <year>2018</year>;<volume>47</volume>(<issue>5</issue>):<fpage>1328</fpage>-<lpage>1341</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jmri.25883</pub-id><?supplied-pmid 29090500?><pub-id pub-id-type="pmid">29090500</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r57">
                <label>57</label>
                <mixed-citation publication-type="webpage"><person-group><collab>Research Gate</collab></person-group>. Toward a 7T MRI protocol for the evaluation of early osteoarthritis in knee cartilage. Accessed January 24, 2022. <ext-link xlink:href="https://www.researchgate.net/profile/Daniel-Park-21/publication/303893184_Toward_a_7T_MRI_protocol_for_the_evaluation_of_early_osteoarthritis_in_knee_cartilage/links/575ac7c508aec91374a618d5/Toward-a-7T-MRI-protocol-for-the-evaluation-of-early-osteoarthritis-in-knee-cartilage.pdf" ext-link-type="uri">https://www.researchgate.net/profile/Daniel-Park-21/publication/303893184_Toward_a_7T_MRI_protocol_for_the_evaluation_of_early_osteoarthritis_in_knee_cartilage/links/575ac7c508aec91374a618d5/Toward-a-7T-MRI-protocol-for-the-evaluation-of-early-osteoarthritis-in-knee-cartilage.pdf</ext-link></mixed-citation>
              </ref>
              <ref id="zoi220042r58">
                <label>58</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dam</surname><given-names>EB</given-names></string-name>, <string-name><surname>Byrjalsen</surname><given-names>I</given-names></string-name>, <string-name><surname>Karsdal</surname><given-names>MA</given-names></string-name>, <string-name><surname>Qvist</surname><given-names>P</given-names></string-name>, <string-name><surname>Christiansen</surname><given-names>C</given-names></string-name></person-group>. <article-title>Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2009</year>;<volume>17</volume>(<issue>3</issue>):<fpage>384</fpage>-<lpage>389</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.joca.2008.07.009</pub-id><?supplied-pmid 18768336?><pub-id pub-id-type="pmid">18768336</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r59">
                <label>59</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lotz</surname><given-names>M</given-names></string-name>, <string-name><surname>Martel-Pelletier</surname><given-names>J</given-names></string-name>, <string-name><surname>Christiansen</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Value of biomarkers in osteoarthritis: current status and perspectives</article-title>. <source>Ann Rheum Dis</source>. <year>2013</year>;<volume>72</volume>(<issue>11</issue>):<fpage>1756</fpage>-<lpage>1763</lpage>. doi:<pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203726</pub-id><?supplied-pmid 23897772?><pub-id pub-id-type="pmid">23897772</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r60">
                <label>60</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Miller</surname><given-names>AD</given-names></string-name>, <string-name><surname>Subramanian</surname><given-names>A</given-names></string-name>, <string-name><surname>Viljoen</surname><given-names>HJ</given-names></string-name></person-group>. <article-title>Theoretically proposed optimal frequency for ultrasound induced cartilage restoration</article-title>. <source>Theor Biol Med Model</source>. <year>2017</year>;<volume>14</volume>(<issue>1</issue>):<fpage>21</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12976-017-0067-4</pub-id><?supplied-pmid 29132387?><pub-id pub-id-type="pmid">29132387</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r61">
                <label>61</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Miller</surname><given-names>AD</given-names></string-name>, <string-name><surname>Chama</surname><given-names>A</given-names></string-name>, <string-name><surname>Louw</surname><given-names>TM</given-names></string-name>, <string-name><surname>Subramanian</surname><given-names>A</given-names></string-name>, <string-name><surname>Viljoen</surname><given-names>HJ</given-names></string-name></person-group>. <article-title>Frequency sensitive mechanism in low-intensity ultrasound enhanced bioeffects</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>8</issue>):<elocation-id>e0181717</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0181717</pub-id><?supplied-pmid 28763448?><pub-id pub-id-type="pmid">28763448</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220042r62">
                <label>62</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Miller</surname><given-names>AD</given-names></string-name>, <string-name><surname>Subramanian</surname><given-names>A</given-names></string-name>, <string-name><surname>Viljoen</surname><given-names>HJ</given-names></string-name></person-group>. <article-title>A nonlinear model of cell interaction with an acoustic field</article-title>. <source>J Biomech</source>. <year>2017</year>;<volume>56</volume>:<fpage>83</fpage>-<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jbiomech.2017.03.007</pub-id><?supplied-pmid 28372796?><pub-id pub-id-type="pmid">28372796</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI220042-1">
              <supplementary-material id="note-ZOI220042-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>
Trial Protocol
</p>
                </caption>
                <media xlink:href="jamanetwopen-e220632-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p><bold>eTable 1.</bold> Average Analgesia by Group</p>
                  <p><bold>eTable 2.</bold> NSAID Use During the Trial</p>
                  <p><bold>eFigure.</bold> Mean WOMAC Pain Subscale Over Time by Treatment Group</p>
                </caption>
                <media xlink:href="jamanetwopen-e220632-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e220632-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
